Press and Media
Leading contract development and manufacturing organizations (CDMO’S) can offer new solutions to help meet the rapidly evolving vaccine market.
The renewed interest in the vaccine market has created challenges in the production and manufacture of complex biologic based vaccines. New solutions are needed to take advantage of this rapidly evolving market with an estimated sales increase of almost 20 percent to about $33 billion by 2013. In this issue of Contract Pharma, Dr. David Brett, Product & Service Manager, Vetter Pharma International GmbH offers his thoughts on how leading CDMO’s with their innovative manufacturing facilities, can realize potential solutions for this rapidly emerging growth segment and deliver secure supply for public health.